Total Payments
$6,021
2024 Payments
$1,261
Companies
17
Transactions
343
Medicare Patients
3,473
Medicare Billing
$544,315
Payment Breakdown by Category
Food & Beverage$5,864 (97.4%)
Education$156.47 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,864 | 340 | 97.4% |
| Education | $156.47 | 3 | 2.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $1,738 | 92 | $0 (2024) |
| ABBVIE INC. | $873.44 | 49 | $0 (2024) |
| Janssen Biotech, Inc. | $702.70 | 50 | $0 (2023) |
| Allergan, Inc. | $696.99 | 55 | $0 (2020) |
| Insmed, Inc. | $461.49 | 20 | $0 (2024) |
| Merck Sharp & Dohme LLC | $419.95 | 23 | $0 (2024) |
| Gilead Sciences, Inc. | $292.74 | 16 | $0 (2024) |
| Astellas Pharma US Inc | $250.41 | 13 | $0 (2024) |
| Janssen Products, LP | $156.47 | 3 | $0 (2021) |
| Paratek Pharmaceuticals, Inc. | $120.54 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,261 | 57 | ViiV Healthcare Company ($423.95) |
| 2023 | $1,317 | 69 | ViiV Healthcare Company ($397.66) |
| 2022 | $850.19 | 52 | ViiV Healthcare Company ($256.83) |
| 2021 | $478.60 | 24 | ViiV Healthcare Company ($160.92) |
| 2020 | $432.80 | 28 | Allergan, Inc. ($203.83) |
| 2019 | $498.98 | 36 | ViiV Healthcare Company ($162.51) |
| 2018 | $469.21 | 37 | Allergan Inc. ($159.02) |
| 2017 | $713.62 | 40 | Janssen Biotech, Inc. ($181.66) |
All Payment Transactions
343 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.70 | General |
| Category: HIV | ||||||
| 12/13/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: HIV | ||||||
| 12/10/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $29.97 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/03/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $29.57 | General |
| Category: HIV | ||||||
| 11/25/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $24.98 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/21/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $27.15 | General |
| Category: HIV | ||||||
| 11/07/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: ANTIFUNGALS | ||||||
| 10/28/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), ZERBAXA | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $32.76 | General |
| Category: HIV | ||||||
| 10/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $2.68 | General |
| 10/22/2024 | ABBVIE INC. | DALVANCE (Drug), TEFLARO, AVYCAZ | Food and Beverage | In-kind items and services | $4.11 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.98 | General |
| 09/20/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: HIV | ||||||
| 09/16/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/12/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: HIV | ||||||
| 09/10/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa | Food and Beverage | In-kind items and services | $17.10 | General |
| Category: ANTIFUNGALS | ||||||
| 09/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.92 | General |
| 08/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.83 | General |
| 08/23/2024 | Cumberland Pharmaceuticals, Inc. | VIBATIV (Drug) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: INFECTIONS AND INFECTIOUS DISEASES | ||||||
| 08/22/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $10.90 | General |
| 08/15/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $30.48 | General |
| Category: Respiratory | ||||||
| 08/15/2024 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $8.18 | General |
| Category: HIV | ||||||
| 08/13/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $30.59 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/12/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 911 | 1,548 | $357,990 | $137,765 |
| 2022 | 8 | 828 | 1,326 | $298,599 | $117,819 |
| 2021 | 7 | 841 | 1,341 | $288,938 | $120,810 |
| 2020 | 6 | 893 | 1,780 | $281,585 | $167,921 |
Total Patients
3,473
Total Services
5,995
Medicare Billing
$544,315
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 376 | 433 | $123,021 | $49,023 | 39.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 310 | 646 | $110,695 | $44,453 | 40.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 161 | $43,757 | $17,059 | 39.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 50 | 83 | $21,253 | $8,614 | 40.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 16 | 146 | $32,850 | $7,923 | 24.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 28 | $10,400 | $4,232 | 40.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $5,707 | $2,324 | 40.7% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 12 | 12 | $5,189 | $2,090 | 40.3% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 23 | 23 | $5,118 | $2,049 | 40.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 302 | 328 | $97,432 | $38,573 | 39.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 284 | 604 | $93,383 | $37,179 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 69 | 133 | $36,603 | $13,613 | 37.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 50 | 133 | $29,521 | $11,904 | 40.3% |
| 99219 | Initial hospital observation care per day, typically 50 minutes | Facility | 2022 | 56 | 60 | $17,365 | $6,772 | 39.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 34 | 35 | $15,113 | $6,088 | 40.3% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2022 | 21 | 21 | $4,749 | $1,914 | 40.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $4,434 | $1,776 | 40.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 291 | 680 | $96,402 | $42,901 | 44.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 319 | 342 | $101,567 | $40,908 | 40.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 54 | 102 | $28,273 | $11,237 | 39.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 65 | 104 | $22,308 | $9,410 | 42.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 50 | 51 | $21,644 | $8,930 | 41.3% |
| 99219 | Hospital observation care, typically 50 minutes | Facility | 2021 | 50 | 50 | $14,407 | $5,759 | 40.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 12 | 12 | $4,337 | $1,664 | 38.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 261 | 759 | $75,900 | $48,498 | 63.9% |
About Janet Toirac Perdomo
Janet Toirac Perdomo is a Infectious Disease healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2009. The National Provider Identifier (NPI) number assigned to this provider is 1871729293.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Janet Toirac Perdomo has received a total of $6,021 in payments from pharmaceutical and medical device companies, with $1,261 received in 2024. These payments were reported across 343 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($5,864).
As a Medicare-enrolled provider, Toirac Perdomo has provided services to 3,473 Medicare beneficiaries, totaling 5,995 services with total Medicare billing of $544,315. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Miami, FL
- Active Since 06/01/2009
- Last Updated 10/27/2016
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1871729293
Products in Payments
- DOVATO (Drug) $1,031
- DALVANCE (Drug) $927.90
- AVYCAZ (Drug) $642.53
- Arikayce (Drug) $461.49
- PREZCOBIX (Drug) $429.98
- SYMTUZA (Drug) $344.17
- APRETUDE (Biological) $288.53
- DIFICID (Drug) $176.39
- TRIUMEQ (Drug) $173.65
- PIFELTRO (Drug) $169.59
- Cresemba (Drug) $126.14
- NUZYRA (Drug) $120.54
- CABENUVA (Biological) $104.17
- JULUCA (Drug) $102.30
- Symtuza (Drug) $85.02
- CRESEMBA (Drug) $77.83
- Fetroja (Drug) $64.80
- Rezzayo (Drug) $50.62
- MYCAMINE (Drug) $46.44
- XERAVA (Drug) $39.65
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Miami
Douglas Brust, M.d, M.D
Infectious Disease — Payments: $450,213
Infectious Disease $450,213
Ricardo Fonseca Franco
Infectious Disease — Payments: $135,298
Infectious Disease $135,298
Hector Bolivar, Md, MD
Infectious Disease — Payments: $105,997
Infectious Disease $105,997
Jorge Murillo, Md, MD
Infectious Disease — Payments: $85,760
Infectious Disease $85,760
Dushyantha Jayaweera, Md, MD
Infectious Disease — Payments: $79,219
Infectious Disease $79,219
Dr. Lilian Abbo, Md, MD
Infectious Disease — Payments: $69,205
Infectious Disease $69,205